JP4786866B2 - クロライドチャンネルオープナーとしてのプロスタグランジンアナログ - Google Patents

クロライドチャンネルオープナーとしてのプロスタグランジンアナログ Download PDF

Info

Publication number
JP4786866B2
JP4786866B2 JP2003533944A JP2003533944A JP4786866B2 JP 4786866 B2 JP4786866 B2 JP 4786866B2 JP 2003533944 A JP2003533944 A JP 2003533944A JP 2003533944 A JP2003533944 A JP 2003533944A JP 4786866 B2 JP4786866 B2 JP 4786866B2
Authority
JP
Japan
Prior art keywords
compound
prostaglandin
dihydro
alkyl
keto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003533944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504836A5 (enExample
JP2005504836A (ja
Inventor
隆司 上野
ジョン・カッポレッティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4786866(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of JP2005504836A publication Critical patent/JP2005504836A/ja
Publication of JP2005504836A5 publication Critical patent/JP2005504836A5/ja
Application granted granted Critical
Publication of JP4786866B2 publication Critical patent/JP4786866B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003533944A 2001-08-31 2002-08-29 クロライドチャンネルオープナーとしてのプロスタグランジンアナログ Expired - Lifetime JP4786866B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31591701P 2001-08-31 2001-08-31
US60/315,917 2001-08-31
US37210402P 2002-04-15 2002-04-15
US60/372,104 2002-04-15
PCT/JP2002/008705 WO2003030912A1 (en) 2001-08-31 2002-08-29 Prostaglandin analogs as chloride channel opener

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011001763A Division JP5568021B2 (ja) 2001-08-31 2011-01-07 クロライドチャンネルオープナーとしてのプロスタグランジンアナログ

Publications (3)

Publication Number Publication Date
JP2005504836A JP2005504836A (ja) 2005-02-17
JP2005504836A5 JP2005504836A5 (enExample) 2006-01-05
JP4786866B2 true JP4786866B2 (ja) 2011-10-05

Family

ID=26980134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003533944A Expired - Lifetime JP4786866B2 (ja) 2001-08-31 2002-08-29 クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
JP2011001763A Expired - Lifetime JP5568021B2 (ja) 2001-08-31 2011-01-07 クロライドチャンネルオープナーとしてのプロスタグランジンアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011001763A Expired - Lifetime JP5568021B2 (ja) 2001-08-31 2011-01-07 クロライドチャンネルオープナーとしてのプロスタグランジンアナログ

Country Status (11)

Country Link
US (2) US7064148B2 (enExample)
EP (1) EP1420794B1 (enExample)
JP (2) JP4786866B2 (enExample)
AR (1) AR036391A1 (enExample)
AU (1) AU2002330747B2 (enExample)
BR (1) BR0212233A (enExample)
CA (1) CA2458471C (enExample)
MX (1) MXPA04002006A (enExample)
NZ (1) NZ531503A (enExample)
TW (1) TWI298256B (enExample)
WO (1) WO2003030912A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012031202A (ja) * 2002-12-27 2012-02-16 Sucampo Ag 腹部不快感の処置のためのプロスタグランジン誘導体
WO2015049876A1 (ja) 2013-10-04 2015-04-09 国立大学法人東北大学 腎機能障害の予防又は改善剤
US11376287B2 (en) 2016-10-20 2022-07-05 Biofermin Pharmaceutical Co., Ltd. Agent acting on transcellular ion transporter in intestinal tract, agent for activating chloride channel, agent for preventing or treating renal disease, or agent for promoting defecation

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1389116E (pt) * 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN104248763A (zh) * 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
AU2007223469B2 (en) * 2006-02-28 2012-06-07 Sucampo Ag Method and composition for treating chronic obstructive pulmonary disease
JP5427029B2 (ja) * 2006-09-06 2014-02-26 スキャンポ・アーゲー 消化管の重炭酸分泌を促進するための方法および組成物
US20080207759A1 (en) * 2007-02-27 2008-08-28 Sucampo Ag Method for protecting mitochondria
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US8551534B2 (en) * 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
SG178315A1 (en) * 2009-08-07 2012-03-29 Scipharm Sarl Composition for the treatment of cystic fibrosis
MX342548B (es) * 2009-09-18 2016-10-04 Merck Sharp & Dohme Corp * Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.
HUE031652T2 (en) 2011-02-07 2017-07-28 Scipharm Sarl New composition for treating cystic fibrosis
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AU2012267938B2 (en) 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
US10724986B2 (en) 2012-11-29 2020-07-28 Indiana University Research & Technology Corporation Dielectric electrolyte measurement device
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56152455A (en) * 1980-04-28 1981-11-26 Ono Pharmaceut Co Ltd Prostaglandin analog, compound, its preparation, and drug composition comprising it
JPH02109A (ja) * 1987-10-02 1990-01-05 Ueno Seiyaku Oyo Kenkyusho:Kk 下剤
JPH03218315A (ja) * 1989-11-22 1991-09-25 Ueno Seiyaku Oyo Kenkyusho:Kk ガス交換機能不全処置剤
WO1999018968A1 (en) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Portal hypertension inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE43462B1 (en) * 1975-06-23 1981-03-11 Pfizer Substituted tetranorprostaglandins
US4091207A (en) * 1976-04-22 1978-05-23 Pfizer Inc. Prostaglandin intermediate including oxathio heterocyclic ring
IT1098350B (it) * 1977-07-28 1985-09-07 Upjohn Co Derivati prostaglandinici
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3873007T2 (de) 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0455448B1 (en) 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
CA2279267C (en) * 1997-11-28 2010-01-12 R-Tech Ueno, Ltd. Use of 15-ketoprostaglandin e compounds as endothelin antagonist
WO1999061029A1 (en) * 1998-05-25 1999-12-02 Taisho Pharmaceutical Co., Ltd. Sleep inducing agent
NZ521464A (en) 2000-03-24 2004-09-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
JP4183943B2 (ja) 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
FR2829293B1 (fr) * 2001-08-31 2003-11-14 Centre Nat Rech Scient Memoire moleculaire et son procede de fabrication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56152455A (en) * 1980-04-28 1981-11-26 Ono Pharmaceut Co Ltd Prostaglandin analog, compound, its preparation, and drug composition comprising it
JPH02109A (ja) * 1987-10-02 1990-01-05 Ueno Seiyaku Oyo Kenkyusho:Kk 下剤
JPH03218315A (ja) * 1989-11-22 1991-09-25 Ueno Seiyaku Oyo Kenkyusho:Kk ガス交換機能不全処置剤
WO1999018968A1 (en) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Portal hypertension inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012031202A (ja) * 2002-12-27 2012-02-16 Sucampo Ag 腹部不快感の処置のためのプロスタグランジン誘導体
WO2015049876A1 (ja) 2013-10-04 2015-04-09 国立大学法人東北大学 腎機能障害の予防又は改善剤
US11376287B2 (en) 2016-10-20 2022-07-05 Biofermin Pharmaceutical Co., Ltd. Agent acting on transcellular ion transporter in intestinal tract, agent for activating chloride channel, agent for preventing or treating renal disease, or agent for promoting defecation

Also Published As

Publication number Publication date
JP5568021B2 (ja) 2014-08-06
US20030130352A1 (en) 2003-07-10
CA2458471C (en) 2012-07-31
CA2458471A1 (en) 2003-04-17
EP1420794A1 (en) 2004-05-26
WO2003030912A1 (en) 2003-04-17
TWI298256B (en) 2008-07-01
JP2005504836A (ja) 2005-02-17
NZ531503A (en) 2006-01-27
JP2011102313A (ja) 2011-05-26
EP1420794B1 (en) 2017-12-27
AR036391A1 (es) 2004-09-08
US20060122411A1 (en) 2006-06-08
AU2002330747B2 (en) 2007-07-19
MXPA04002006A (es) 2004-06-07
US7064148B2 (en) 2006-06-20
BR0212233A (pt) 2004-10-05
US7253295B2 (en) 2007-08-07

Similar Documents

Publication Publication Date Title
JP5568021B2 (ja) クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AU2002330747A1 (en) Prostaglandin analogs as chloride channel opener
JP2592204B2 (ja) 眼圧降下剤
US8871752B2 (en) Method for modulating stem cell growth
US20120225938A1 (en) Method for treating central nervous system disorders
EP1140108B1 (en) Method and composition for treatment of female sexual dysfunction
US6956056B2 (en) Method for providing a cathartic effect
US6441033B1 (en) 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
JPH0770054A (ja) 生化学的拮抗および疾患処置剤
HK1252353A1 (zh) 治疗精神分裂症的方法
JP2003526660A (ja) 高眼圧症および緑内障の治療
JP2014515004A (ja) イオン輸送体の調節方法
HK1196278A (en) Method for treating schizophrenia
MX2007009094A (es) Metodo y composiciones para el tratamiento de trastornos del sistema nervioso central.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110714

R150 Certificate of patent or registration of utility model

Ref document number: 4786866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140722

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140722

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140722

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R314531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R314533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350